MANKIND PHARMA
|
The Current P/E Ratio of MANKIND PHARMA is 47.61.
| Share Price | ₹2,369.0 | Oct 13,2026 |
| Market Cap | ₹97,839.7 Cr | |
| Earnings-TTM | ₹2,055.1 Cr | TTM-Consolidated Results |
| Price/Earnings | 47.61x | Calculated as Market Cap/Earnings |
|---|---|---|
| Explore Stock Analytics | ||
Definition & Calculation of PE (Price/Earnings) ratio of MANKIND PHARMA
P/E =
Market Capitalization
/ Net Income
or, using per-share numbers:
P/E = Stock Price /
Earnings Per Share (EPS)
Current Market Cap [ ₹97,839.7 Cr] as on Oct 13,2026
(/) Earnings [ ₹2,055.1 Cr] based on TTM-Consolidated Results
(=) P/E Ratio [ 47.61x ]
Thus, for MANKIND PHARMA , the investors are currently willing to pay 47.61 times earnings to own 1 share of the company.
PE Multiples are the most widely used valuation multiple in practice.
Since P/E ratio uses Net Income in the calculation, P/E multiples are not always reliable for valuing companies with negative earnings.
In such cases, you may consider using Price to Book ratio or Price to Sales ratio of MANKIND PHARMA !
P/E ratios, also, would not adjust for differences in the capital structure between companies.
The chart below summarizes the trend in P/E Ratio of MANKIND PHARMA over the last five years.
Historical PE (Price/Earnings) ratio chart of MANKIND PHARMA
PE Ratio Performance Analysis for MANKIND PHARMA
- MANKIND PHARMA 's p/e ratio for fiscal years ending Mar2026 to Mar2022 averaged 28.32x.
- MANKIND PHARMA 's operated at median p/e ratio of 43.29x from fiscal years ending March 2018 to 2022.
- Looking back at the last 5 fiscal years, MANKIND PHARMA 's p/e ratio peaked in Mar2025 at 50.22x.
- MANKIND PHARMA 's p/e ratio hit its five-year low in Mar2023 of 0x.
How does MANKIND PHARMA 's P/E Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?
| Peer Comparison (Pharmaceuticals & Drugs Industry) | Earnings-TTM (Cr) | PE Ratio | Market Cap |
|---|---|---|---|
| MANKIND PHARMA | 2,055.11 | 47.61 | 97,839.7 |
| SUN PHARMACEUTICAL INDUSTRIES LTD | 12,172.70 | 34.87 | 424,466.0 |
| DIVIS LABORATORIES LTD | 2,925.00 | 84.18 | 246,222.0 |
| TORRENT PHARMACEUTICALS LTD | 2,156.00 | 81.77 | 176,300.0 |
| CIPLA LTD | 3,364.84 | 31.93 | 107,447.0 |
| DR REDDYS LABORATORIES LTD | 3,169.30 | 32.65 | 103,471.0 |
| LUPIN LTD | 5,551.01 | 16.15 | 89,628.8 |
| ZYDUS LIFESCIENCES LTD | 4,492.20 | 25.11 | 112,818.0 |
| AUROBINDO PHARMA LTD | 3,712.74 | 26.08 | 96,836.1 |
| LAURUS LABS LTD | 1,090.76 | 101.60 | 110,823.0 |
| BIOCON LTD | 416.40 | 137.39 | 57,210.4 |
Pharmaceuticals & Drugs Industry Benchmark (Top 10) PE Analysis vs MANKIND PHARMA 's P/E Ratio
| Top 10 Industry Peers | PE Ratio |
|---|---|
| Min industry PE | 16.15x |
| Max industry PE | 137.39x |
| Median industry PE | 34.87x |
| Average industry PE | 56.30x |
You may also like the below Video Courses